Biomarker-based adaptive trials for patients with glioblastoma - Lessons from I-SPY 2

Brian M. Alexander, Patrick Y. Wen, Lorenzo Trippa, David A. Reardon, Wai Kwan Alfred Yung, Giovanni Parmigiani, Donald A. Berry

Research output: Contribution to journalArticle

Abstract

The traditional clinical trials infrastructure may not be ideally suited to evaluate the numerous therapeutic hypotheses that result from the increasing number of available targeted agents combined with the various methodologies to molecularly subclassify patients with glioblastoma. Additionally, results from smaller screening studies are rarely translated to successful larger confirmatory studies, potentially related to a lack of efficient control arms or the use of unvalidated surrogate endpoints. Streamlining clinical trials and providing a flexible infrastructure for biomarker development is clearly needed for patients with glioblastoma. The experience developing and implementing the I-SPY studies in breast cancer may serve as a guide to developing such trials in neuro-oncology.

Original languageEnglish (US)
Pages (from-to)972-978
Number of pages7
JournalNeuro-Oncology
Volume15
Issue number8
DOIs
StatePublished - Aug 2013
Externally publishedYes

    Fingerprint

Keywords

  • adaptive
  • Bayesian
  • biomarker
  • clinical trials
  • glioblastoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Clinical Neurology

Cite this

Alexander, B. M., Wen, P. Y., Trippa, L., Reardon, D. A., Yung, W. K. A., Parmigiani, G., & Berry, D. A. (2013). Biomarker-based adaptive trials for patients with glioblastoma - Lessons from I-SPY 2. Neuro-Oncology, 15(8), 972-978. https://doi.org/10.1093/neuonc/not088